E1 ReplicatedModerate confidencePEM not requiredRCTPeer-reviewedReviewed
Standard · 3 min
Cost-Utility of Home-Based Fatigue Self-Management versus Usual Care for the Treatment of Chronic Fatigue Syndrome.
Meng, Hongdao, Friedberg, Fred · Fatigue : biomedicine, health & behavior · 2017 · DOI
Quick Summary
This study compared a low-cost, home-based self-management program for fatigue (based on cognitive behavioral therapy) with standard medical care for people with severe ME/CFS. Over one year, the self-management program was found to be more cost-effective than usual care—meaning it helped people feel better while costing less overall. The program was popular with participants and had very few people drop out.
Why It Matters
Cost-effectiveness evidence is crucial for healthcare policy and patient access, as it demonstrates that ME/CFS management need not be expensive or burdensome. This study provides economic justification for offering home-based self-management programs in primary care settings, potentially expanding treatment availability for patients with severe ME/CFS who may lack access to specialist services.
Observed Findings
FSM intervention dominated usual care in incremental cost-utility ratios in both intention-to-treat and complete-cases analyses.
Net monetary benefit analysis showed FSM had higher probability of positive net benefit across all willingness-to-pay thresholds for fatigue symptom management.
Baseline individual characteristics were similar between the two groups, supporting randomization validity.
The FSM intervention was well-received by participants with only minimal attrition.
Total costs (direct, indirect, and intervention) favored FSM over the 12-month follow-up period.
Inferred Conclusions
Home-based fatigue self-management is a cost-effective treatment option for primary care patients with severe CFS.
Low-cost self-delivered cognitive behavioral interventions can achieve positive health economic outcomes without requiring expensive clinical infrastructure.
FSM should be considered as a viable treatment alternative to usual care in primary care settings.
Remaining Questions
Do the cost-effectiveness and quality-of-life benefits of FSM persist beyond 12 months, or do costs increase due to relapse or loss of motivation?
How does FSM efficacy vary across different ME/CFS phenotypes, disease severity levels, or demographic groups?
What This Study Does Not Prove
This study does not prove that cognitive behavioral self-management addresses the underlying biological mechanisms of ME/CFS, nor does it establish that it works equally well for all CFS phenotypes or severity levels. The cost-effectiveness findings are limited to the one-year follow-up period and do not demonstrate whether benefits persist or costs change over longer timeframes. Additionally, correlation between improved QALYs and the intervention does not establish causation—baseline differences in motivation or symptom trajectory could confound results.
Tags
Symptom:Fatigue
Phenotype:Severe
Method Flag:PEM Not DefinedWeak Case DefinitionSmall SampleSevere ME Included
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
What are the mechanisms by which self-delivered cognitive behavioral intervention produces cost reductions—is it reduced healthcare utilization, improved work capacity, or both?
How does this intervention compare in cost-effectiveness to other established ME/CFS treatments, pharmacological or otherwise?